Last reviewed · How we verify
Influenza vaccine GSK2340274A
Influenza vaccine GSK2340274A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention.
GSK2340274A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.
GSK2340274A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens. Used for Influenza prevention.
At a glance
| Generic name | Influenza vaccine GSK2340274A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an influenza vaccine candidate, GSK2340274A works by presenting influenza viral antigens to the immune system to generate protective antibody and T-cell responses. This enables the body to recognize and mount a rapid immune defense against natural influenza infection. The specific formulation and adjuvant strategy of GSK2340274A are proprietary to GlaxoSmithKline's vaccine development program.
Approved indications
- Influenza prevention
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age (PHASE3)
- Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older (PHASE4)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) (PHASE2)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old (PHASE2)
- Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults (PHASE1)
- Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years (PHASE2)
- Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children (PHASE2)
- Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine GSK2340274A CI brief — competitive landscape report
- Influenza vaccine GSK2340274A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Influenza vaccine GSK2340274A
What is Influenza vaccine GSK2340274A?
How does Influenza vaccine GSK2340274A work?
What is Influenza vaccine GSK2340274A used for?
Who makes Influenza vaccine GSK2340274A?
What drug class is Influenza vaccine GSK2340274A in?
What development phase is Influenza vaccine GSK2340274A in?
What are the side effects of Influenza vaccine GSK2340274A?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention
- Compare: Influenza vaccine GSK2340274A vs similar drugs
- Pricing: Influenza vaccine GSK2340274A cost, discount & access